University of Toronto

University of Saskatchewan

Shanghaitech University

Shane Miersch

Sachdev Singh Sidhu

Guohua Pan

Clarence Ronald Geyer

Haiming Huang

Sachedv S Sidhu

Donghui Wu

Shusu Liu

Provided are antibodies or fragments thereof having binding specificity to anti-IL-18 receptor alpha or beta. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and inflammatory and autoimmune diseases are also provided.

Human antibodies to human interleukin 18 receptor alpha or beta

An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.

EGFR-binding agents and uses thereof

Growing community of inventors

Toronto, Canada

Shane Miersch